Pharmacokinetics of Antiplatelet Drugs in Diabetic pAtients
Status:
Withdrawn
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
Clopidogrel efficacy appears diminished in patients with type 2 diabetes (T2D) who continue
to show an increased risk of adverse cardiovascular events and mortality compared to those
without T2D.The aim of the first project is to describe the pharmacokinetic (PK) profile of
three antiplatelet drugs in 4 groups of patients according to their diabetic or non-diabetic
status. To this end, PK profiles will be determined after a single oral dose of 300 mg
clopidogrel, 60 mg prasugrel and 180 mg ticagrelor in patients (n=108); 1) with T2D and good
glycemic control; 2) with T2D and poor glycemic control; 3) with insulin-treated diabetes;
and 4) non-diabetic subjects.
Phase:
Phase 4
Details
Lead Sponsor:
Centre hospitalier de l'Université de Montréal (CHUM)
Collaborator:
Centre de Recherche du Centre Hospitalier de l'Université de Montréal